NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
Oblato, Inc.
Fuda Cancer Hospital, Guangzhou
Fuda Cancer Hospital, Guangzhou
Southwest Hospital, China
Endeavor Health
M.D. Anderson Cancer Center
INSYS Therapeutics Inc